RGM.20.004 – DIABULC (Diabetic Ulcera: Novel Integrated Therapy and Monitoring)

Route: Regenerative medicine: game changer moving to broad areas of application

Cluster question: 100 How can we use cells, stem cells, and biomaterials to engineer and regenerate tissues and organs?

Approach: patient-motivated/driven multidisciplinary consortium that combine patient demands and input with experimental clinical therapy, state-of-the art antimicrobial peptides, clinical application of stem cell technology, biological understanding of underlying mechanisms and integration of modern monitoring.

Rationale: Chronic diabetic ulcers are nonhealing and frequently demand amputation(5 year patient survival is 35%). Current therapies include revascularisation, wound dressings and invasive wound debridement whihc benefit a limited fraction of diabetics on the long term. The recurring difficult-to-treat microbial infections, often as antibiotic impenetrable biofilms, poses an additional heavy burden on the wound healing process. The diabetes patients and clinicians in the consortium translate the need for novel treatment and monitoring modalities
A definitive treatment of chronic wounds demands an combined approach that eradicates infections while normalizing perfusion and wound healing. The research groups in the consortium originate from various disciplines and have developed novel state-of-the-art antimicrobials while other groups developed monitoring techniques that allow to detect infections in real time. Other participating groups showed that adipose tissue and ditto stem cells promote dermal wound healing, while yet other partners assessed the regenerative qualities of so-called extracellular matrix i.e. the ‘glue’ that keeps tissues together. The strength and novelty of DIABULC, is that we for the first time, combine the input and expertise of the patients, clinicians and basic / translational scientists with the expertise from industry into novel therapy and monitoring to harness and definitively heal infected chronic diabetic ulcers.

DIABULC will improve the Quality of Life through Regenerative Medicine.


Antimicrobials, Chronic Ulcers, diabetes, Infection, Monitoring, SVF, Wound Healing

Other organisations

AMC, Aspect, Aspen Pharma, HAN, HCM, Lambert, Leiden Universitair Medisch Centrum (LUMC), MTx, Radboud Medical Center (RUMC), TNO


Organisation University Medical Center Groningen (UMCG)
Name Prof.dr. M.C. (Marco) Harmsen
E-mail m.c.harmsen@umcg.nl
Website https://www.rug.nl/staff/m.c.harmsen/research